Literature DB >> 10370955

[Leydig cell testicular tumors. A series of 10 observations].

A Kalfon1, F Abram, F Kirsch-Noir, C Tchovelidze, G Arvis.   

Abstract

OBJECTIVES: To define the clinical and laboratory characteristics and natural history of Leydig cell tumours in order to define a general management plan.
MATERIAL AND METHODS: The files of 10 patients operated for Leydig cell testicular tumour between 1982 and 1996 were studied retrospectively.
RESULTS: In nine out of ten cases, the presenting complaint was gynaecomastia, erectile dysfunction or infertility. In every case, serum testosterone was normal or low and oestradiol was normal or elevated. Eight patients were treated by radical orchidectomy, and two by subcapsular orchidectomy. The course was favourable in 9 out of 10 cases in the absence of any other treatment. Only one patient had an immediately malignant form with a fatal outcome.
CONCLUSION: Although many teams prefer total orchidectomy because of the diagnostic difficulty associated with malignant forms, simple subcapsular orchidectomy should become the first-line treatment, provided it is subsequently followed by close surveillance, as it preserves maximum fertility, and these tumours usually have a favourable prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10370955

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  2 in total

1.  Testicle-sparing surgery versus radical orchiectomy in the management of Leydig cell tumors: results from a multicenter study.

Authors:  Florian Laclergerie; Guillaume Mouillet; Alexandre Frontczak; Loïc Balssa; Pascal Eschwege; Christian Saussine; Stéphane Larré; Luc Cormier; Antoine Thiery Vuillemin; François Kleinclauss
Journal:  World J Urol       Date:  2017-12-11       Impact factor: 4.226

2.  Leydig cell hyperplasia revealed by gynecomastia.

Authors:  Mohamed Fadl Tazi; Soufiane Mellas; Mohamed Jamal El Fassi; Moulay Hassan Farih
Journal:  Rev Urol       Date:  2008
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.